Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter — ultra-fast Hanzi study All 1,152 characters from the aioLingua manual Abstract • About • The 20 audio files ← aioLingua Chinese Online ← Chinese aioLingua PDF

Pulmonary Hypertension

Free Subscription Articles published in Chest Retrieve available abstracts of 100 articles: HTML format

Single Articles

November 2025
1. MARTIN DE MIGUEL I, Lopez-Guarch CJ, Segura de La Cal T, Nieto SH, et al
   Chronic thromboembolic pulmonary disease with exercise pulmonary hypertension - A non-invasive model to predict exercise hemodynamics.
   Chest. 2025 Nov 12:S0012-3692(25)05680-6. doi: 10.1016/j.chest.2025.
   PubMed     Abstract available
   
   
   
2. ZEDER K, Kundu S, Siew ED, Annis JS, et al
   Longitudinal Pulmonary Arterial Pressure Trajectories and Clinical Outcome in Kidney Transplantation Patients.
   Chest. 2025;168:1200-1214.
   PubMed     Abstract available
   
   
   October 2025
3. SZWED P, Kurzyna P, Banaszkiewicz-Cyganik M, Kedzierski P, et al
   Impact of elevated Pulmonary Arterial Wedge Pressure on safety and efficacy of balloon pulmonary angioplasty in the treatment of chronic thromboembolic pulmonary hypertension.
   Chest. 2025 Oct 18:S0012-3692(25)05620-X. doi: 10.1016/j.chest.2025.
   PubMed     Abstract available
   
   
   September 2025
4. JOSE A, Sood N, Elwing JM, Akkanti B, et al
   "How I Do It": Pulmonary Hypertension Associated with Interstitial Lung Diseases.
   Chest. 2025 Sep 10:S0012-3692(25)05167-0. doi: 10.1016/j.chest.2025.07.4107.
   PubMed     Abstract available
   
   
   
5. SAVONITTO G, Barbisan D, Ameri P, Lombardi CM, et al
   Characteristics, Prognosis, and European Society of Cardiology and European Respiratory Society Risk Stratification in Patients With Obesity and Pulmonary Arterial Hypertension.
   Chest. 2025;168:749-762.
   PubMed     Abstract available
   
   
   August 2025
6. MUKHERJEE M, Jani VP, Osgueritchian R, Mombeini H, et al
   Echocardiographic Parameters and Risk Prediction in Pulmonary Arterial Hypertension: Insights From the Redefining Pulmonary Hypertension Through Pulmonary Vascular Disease Phenomics Network.
   Chest. 2025;168:502-519.
   PubMed     Abstract available
   
   
   
7. CAO JY, Abdo RM, Wang N, Olsen N, et al
   Prognostic Value of Main Pulmonary Artery Diameter in Pulmonary Arterial Hypertension.
   Chest. 2025;168:476-487.
   PubMed     Abstract available
   
   
   July 2025
8. AUSTIN ED
   Measuring Activity in Pediatric Pulmonary Hypertension: Expanding Opportunities to Advance Clinical Trial Design and Impact.
   Chest. 2025;168:13-15.
   PubMed    
   
   
   
9. LEARY PJ, Rayner SG, Branch KRH, Hogl L, et al
   Effect of Famotidine on Outcomes in Pulmonary Arterial Hypertension: A Randomized Controlled Trial.
   Chest. 2025;168:189-199.
   PubMed     Abstract available
   
   
   June 2025
10. HUANG Z, Diao X, Huo Y, Zhao Z, et al
    Deep Learning-Enhanced Non-Invasive Detection of Pulmonary Hypertension and Subtypes via Chest Radiographs, Validated by Catheterization.
    Chest. 2025 Jun 18:S0012-3692(25)00702-0. doi: 10.1016/j.chest.2025.
    PubMed     Abstract available
    
    
    May 2025
11. MATUSOV Y, Kolaitis NA, Geft D, DesJardin J, et al
    How I do it: Best practices for right heart catheterization in the diagnosis of pulmonary hypertension.
    Chest. 2025 May 16:S0012-3692(25)00579-3. doi: 10.1016/j.chest.2025.
    PubMed     Abstract available
    
    
    
12. MCCARTHY BE, Feng R, Torigian DA, Tong Y, et al
    Epicardial Adipose Tissue as an Independent Risk Factor for Mortality in Pulmonary Arterial Hypertension.
    Chest. 2025;167:1481-1492.
    PubMed     Abstract available
    
    
    April 2025
13. BAILEY M, Frantz R, Minhas J, Cascino T, et al
    The frequency and predictors of pulmonary rehabilitation referrals among patients with pulmonary arterial hypertension: An analysis of the Pulmonary Hypertension Association Registry.
    Chest. 2025 Apr 28:S0012-3692(25)00547-1. doi: 10.1016/j.chest.2025.
    PubMed     Abstract available
    
    
    
14. MOUNSEY LA, Kalaria CJ, Kowal A, Hoenstine C, et al
    Exercise hemodynamics and the evolving definition of precapillary pulmonary hypertension.
    Chest. 2025 Apr 21:S0012-3692(25)00450-7. doi: 10.1016/j.chest.2025.
    PubMed    
    
    
    
15. KUDELKO K, Sung YK, Ventetuolo CE, Kawut S, et al
    National Consortium on Pulmonary Vascular Disease Fellowship Training Summary.
    Chest. 2025;167:1191-1203.
    PubMed     Abstract available
    
    
    
16. WALIGORA M, Kurzyna M, Mularek-Kubzdela T, Skoczylas I, et al
    Effects of beta-Blockers on the Outcomes in Patients With Pulmonary Arterial Hypertension Stratified by the Presence of Comorbid Conditions: A Multicenter Prospective Cohort Study: The Database of Pulmonary Hypertension in the Polish Population (BNP-P
    Chest. 2025;167:1171-1181.
    PubMed     Abstract available
    
    
    March 2025
17. CORDOVA FC, D'Alonzo G
    Phosphodiesterase Inhibitor Therapy in Pulmonary Hypertension-Associated COPD: Revisiting an Old Controversy With Renewed Interest.
    Chest. 2025;167:647-648.
    PubMed    
    
    
    February 2025
18. LECHUGA CG, Raza F, Colebank MJ, Korcarz CE, et al
    Characteristic Pulmonary Impedance With Exercise Detects Abnormal Pulmonary Vascular Response and Uncoupling in Pulmonary Hypertension Resulting From Heart Failure With Preserved Ejection Fraction.
    Chest. 2025 Feb 26:S0012-3692(25)00268-5. doi: 10.1016/j.chest.2025.
    PubMed     Abstract available
    
    
    
19. PLOEGSTRA MJ, Ferreira RJ, Lokhorst C, Gouwy E, et al
    Physical Activity Measured by Hip-Anchored Accelerometry in Pediatric Pulmonary Hypertension: Association with Disease Severity & Estimation of Minimal Important Differences.
    Chest. 2025 Feb 8:S0012-3692(25)00156-4. doi: 10.1016/j.chest.2025.
    PubMed     Abstract available
    
    
    
20. LANGLEBEN D, Lesenko L, Fox BD, Eintracht S, et al
    Ineffectiveness of Sotatercept Therapy in a Patient With Heritable Pulmonary Arterial Hypertension Associated With a Previously Unreported Missense Variant in GDF2, the Gene for Bone Morphogenic Protein-9.
    Chest. 2025;167:e37-e39.
    PubMed     Abstract available
    
    
    
21. MORRIS TA
    Chronic Thromboembolism Phenotypes Aside From Pulmonary Hypertension: "CTE(X)".
    Chest. 2025;167:322-323.
    PubMed    
    
    
    
22. D'ALTO M, Guazzi M
    Unlocking the Hidden Pearls of Using Tricuspid Annulus Plane Systolic Excursion on Pulmonary Arterial Systolic Pressure Ratio in the Prognostic Assessment of Suspected But Unconfirmed or Mild Pulmonary Hypertension.
    Chest. 2025;167:319-321.
    PubMed    
    
    
    
23. JOHN T, Avian A, John N, Eger A, et al
    Prognostic Relevance of Tricuspid Annular Plane Systolic Excursion to Systolic Pulmonary Arterial Pressure Ratio and Its Association With Exercise Hemodynamics in Patients With Normal or Mildly Elevated Resting Pulmonary Arterial Pressure.
    Chest. 2025;167:573-584.
    PubMed     Abstract available
    
    
    January 2025
24. CHAOUAT A, Valentin S, Adir Y
    Phosphodiesterase-5 Inhibitors Show Promise in Improving Survival for Patients With COPD Pulmonary Hypertension: One Step Further But There Is Still a Long Way to Go.
    Chest. 2025;167:16-18.
    PubMed    
    
    
    December 2024
25. GRIFFITHS M, Simpson CE, Yang J, Vaidya D, et al
    Equivalency of Multiple Biomarkers to Clinical Pulmonary Arterial Hypertension Survival Risk Models.
    Chest. 2024;166:1511-1531.
    PubMed     Abstract available
    
    
    November 2024
26. WHITE RJ, El-Kersh K, Rosenkranz S, Franco V, et al
    Treatment with Oral or Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension and Cardiovascular Comorbidities.
    Chest. 2024 Nov 30:S0012-3692(24)05604-6. doi: 10.1016/j.chest.2024.
    PubMed     Abstract available
    
    
    
27. POISSON C, Hlavaty A, Favrolt N, Chaumais MC, et al
    Pulmonary hypertension associated with Trastuzumab-Emtansine: an analysis of French PH registry and WHO pharmacovigilance database.
    Chest. 2024 Nov 19:S0012-3692(24)05562-4. doi: 10.1016/j.chest.2024.
    PubMed     Abstract available
    
    
    
28. HAO L, Xue J
    Improving Diagnosis and Management of Pulmonary Hypertension in Interstitial Lung Disease.
    Chest. 2024;166:e175-e176.
    PubMed    
    
    
    
29. BALANESCU DV, Kane GC
    Redefining Echocardiographic Pulmonary Artery Measurements: Insights Into the Presence of Pulmonary Hypertension.
    Chest. 2024;166:919-920.
    PubMed    
    
    
    
30. GERGES C, Beurnier A, Jais X, Herve P, et al
    Role of Exercise Hemodynamics in the Prediction of Pulmonary Arterial Hypertension in BMPR2 Mutation Carriers.
    Chest. 2024;166:1173-1183.
    PubMed     Abstract available
    
    
    October 2024
31. MOUNSEY LA, Alape Moya D, Wright C, Langer N, et al
    Association between thrombus histopathology and hemodynamic outcomes among patients with chronic thromboembolic pulmonary hypertension undergoing pulmonary endarterectomy.
    Chest. 2024 Oct 23:S0012-3692(24)05395-9. doi: 10.1016/j.chest.2024.
    PubMed    
    
    
    
32. GIGANTE A, Ciurzynski M
    Are There Any New, Useful Echocardiographic Parameters in Identifying Mild Pulmonary Hypertension in Patients With Systemic Sclerosis?
    Chest. 2024;166:668-670.
    PubMed    
    
    
    September 2024
33. INSEL M, El Aini T, Woodhead G, Wig R, et al
    Post Pulmonary Embolism Phenotypes Described by Invasive Cardiopulmonary Exercise Testing.
    Chest. 2024 Sep 3:S0012-3692(24)05134-1. doi: 10.1016/j.chest.2024.
    PubMed     Abstract available
    
    
    
34. FAUVEL C, Gomberg-Maitland M, Benza RL
    Risk Stratification in Pulmonary Hypertension: We Need to "GoDeeper"!
    Chest. 2024;166:420-422.
    PubMed    
    
    
    
35. PRESTON IR, Lewis D, Gomberg-Maitland M
    Using Sotatercept in the Care of Patients With Pulmonary Arterial Hypertension.
    Chest. 2024;166:604-611.
    PubMed     Abstract available
    
    
    August 2024
36. GUGLIN M, Munshi K, Volz E, Bennett M, et al
    Misclassification of Pulmonary Hypertension with Current Hemodynamic Criteria.
    Chest. 2024 Aug 27:S0012-3692(24)05067-0. doi: 10.1016/j.chest.2024.
    PubMed    
    
    
    
37. TELLO K, Yogeswaran A, Majeed RW, Kiely DG, et al
    Phosphodiesterase-5 Inhibitor Treatment is Associated with Improved Survival in Pulmonary Hypertension Associated with COPD in the PVRI GoDeep Meta-Registry.
    Chest. 2024 Aug 23:S0012-3692(24)05046-3. doi: 10.1016/j.chest.2024.
    PubMed     Abstract available
    
    
    
38. JOSE A, Kumar SS, Gorelik L, Friedman SH, et al
    Association of Cardiopulmonary Hemodynamics and Outcomes in Pulmonary Hypertension Following Kidney Transplant: A Multicenter Retrospective Cohort Study.
    Chest. 2024 Aug 22:S0012-3692(24)04938-9. doi: 10.1016/j.chest.2024.
    PubMed     Abstract available
    
    
    
39. SAHAY S, Villasmil Hernandez N, Wang F, Wooten M, et al
    Comparison Between REVEAL Lite 2 and COMPERA 2.0 for Risk Stratification in Pulmonary Arterial Hypertension.
    Chest. 2024;166:373-387.
    PubMed     Abstract available
    
    
    July 2024
40. BAGHERZADEH SP, Celestin BE, Santana EJ, Salerno M, et al
    Novel Reference Equations for Pulmonary Artery Size and Pulsatility Using Echocardiography and their Diagnostic Value in Pulmonary Hypertension.
    Chest. 2024 Jul 16:S0012-3692(24)04615-4. doi: 10.1016/j.chest.2024.06.3805.
    PubMed     Abstract available
    
    
    
41. STRICK DJ, Farber HW, Hill NS, Preston IR, et al
    Group 5 Pulmonary Hypertension Associated With T-Cell Large Granular Lymphocytic Leukemia: Hemodynamics and Treatment.
    Chest. 2024;166:e1-e3.
    PubMed     Abstract available
    
    
    
42. NOSSENT EJ, Smits JA, Seegers C, Meijboom LJ, et al
    Clinical Correlates of a Nonplexiform Vasculopathy in Patients With a Diagnosis of Idiopathic Pulmonary Arterial Hypertension.
    Chest. 2024;166:190-200.
    PubMed     Abstract available
    
    
    June 2024
43. COLALILLO A, Hachulla E, Pellicano C, Smith V, et al
    DLco and echocardiographic parameters in identifying mild pulmonary hypertension in the EUSTAR cohort of systemic sclerosis patients.
    Chest. 2024 Jun 5:S0012-3692(24)00683-4. doi: 10.1016/j.chest.2024.
    PubMed     Abstract available
    
    
    
44. LAMMI MR, Agrawal V, Mathai SC
    Does the Left Heart Know What the Right Heart Is Doing in Patients With Systemic Sclerosis and Pulmonary Hypertension?
    Chest. 2024;165:1288-1290.
    PubMed    
    
    
    
45. CHAROENPONG P, Hall NM, Keller CM, Ram AK, et al
    Overview of Methamphetamine-Associated Pulmonary Arterial Hypertension.
    Chest. 2024;165:1518-1533.
    PubMed     Abstract available
    
    
    May 2024
46. ANG HL, Schulte M, Chan RK, Tan HH, et al
    Pulmonary hypertension in interstitial lung disease: a systematic review and meta-analysis.
    Chest. 2024 May 29:S0012-3692(24)00661-5. doi: 10.1016/j.chest.2024.
    PubMed     Abstract available
    
    
    
47. GENECAND L, Lador F, Montani D, Perneger T, et al
    Is Higher Dose of Inhaled Treprostinil Truly Superior to Lower Dose of Inhaled Treprostinil in Patients With Pulmonary Hypertension Associated With Interstitial Lung Diseases?
    Chest. 2024;165:e161.
    PubMed    
    
    
    
48. CHEN Y, Li J, Li F, Chen Z, et al
    Impact of Epicardial Adipose Tissue on Right Cardiac Function and Prognosis in Pulmonary Arterial Hypertension.
    Chest. 2024;165:1211-1223.
    PubMed     Abstract available
    
    
    
49. RICE JL, Austin ED, Mathai SC, Sahay S, et al
    Genetic Testing in Pulmonary Arterial Hypertension Evaluation: A Patient and Clinician Survey.
    Chest. 2024;165:1224-1227.
    PubMed    
    
    
    April 2024
50. AL-NAAMANI N, Thenappan T
    Left Heart Disease Phenotype in Pulmonary Arterial Hypertension: Considerations for Therapy.
    Chest. 2024;165:766-768.
    PubMed    
    
    
    
51. KEARNEY K, Brown K, Celermajer DS, Collins N, et al
    Impact of Left Heart Disease Risk Factors on Outcomes in Pulmonary Arterial Hypertension Therapy.
    Chest. 2024;165:967-977.
    PubMed     Abstract available
    
    
    March 2024
52. YOGESWARAN A, Gall H, Funderich M, Wilkins MR, et al
    Comparison of contemporary risk scores in all groups of pulmonary hypertension - a PVRI GoDeep meta-registry analysis.
    Chest. 2024 Mar 18:S0012-3692(24)00309-X. doi: 10.1016/j.chest.2024.
    PubMed     Abstract available
    
    
    
53. O'MEARA K, Stone G, Buch E, Brownstein A, et al
    Atrial Arrhythmias in Patients with Pulmonary Hypertension.
    Chest. 2024 Mar 5:S0012-3692(24)00291-5. doi: 10.1016/j.chest.2024.
    PubMed     Abstract available
    
    
    
54. PROVENCHER S, Mai V, Bonnet S
    Managing Pulmonary Arterial Hypertension With Cardiopulmonary Comorbidities.
    Chest. 2024;165:682-691.
    PubMed     Abstract available
    
    
    
55. OROZCO-LEVI M, de Jesus Perez V
    Precision Solutions: A Strategy to Improve Medical Care for Patients With Pulmonary Hypertension in Latin America.
    Chest. 2024;165:669-672.
    PubMed    
    
    
    
56. SAHAY S
    Counterpoint: Should the Use of Upfront Triple Combination Therapy Be Standard of Care in Pulmonary Arterial Hypertension? No.
    Chest. 2024;165:494-496.
    PubMed    
    
    
    
57. WEATHERALD J, Sitbon O
    POINT: Should the Use of Upfront Triple Combination Therapy Be Standard of Care in Pulmonary Arterial Hypertension? Yes.
    Chest. 2024;165:492-494.
    PubMed    
    
    
    February 2024
58. BALASUBRAMANIAN A, Larive B, Horn EM, DuBrock HM, et al
    Health-Related Quality of Life Across the Spectrum of Pulmonary Hypertension.
    Chest. 2024 Feb 12:S0012-3692(24)00155-7. doi: 10.1016/j.chest.2024.
    PubMed     Abstract available
    
    
    
59. FAUVEL C, White RJ, Vanderpool RR, Badagliacca R, et al
    Risk Stratification in Pulmonary Arterial Hypertension: Perhaps Simple Is Not Best?
    Chest. 2024;165:431-436.
    PubMed    
    
    
    
60. MOORE J, Remy J, Altschul E, Chusid J, et al
    Thoracic Applications of Spectral CT Scan.
    Chest. 2024;165:417-430.
    PubMed     Abstract available
    
    
    January 2024
61. FRANTZ RP, Swift AJ
    Advancing Risk Stratification in Pulmonary Arterial Hypertension Through Cardiac MRI: The Need for Collaboration and Standardization.
    Chest. 2024;165:12-13.
    PubMed    
    
    
    
62. CELANT LR, Wessels JN, Marcus JT, Meijboom LJ, et al
    Toward the Implementation of Optimal Cardiac Magnetic Resonance Risk Stratification in Pulmonary Arterial Hypertension.
    Chest. 2024;165:181-191.
    PubMed     Abstract available
    
    
    December 2023
63. LUI JK, Cozzolino M, Winburn M, Trojanowski MA, et al
    Role of Left Ventricular Dysfunction in Systemic Sclerosis-related Pulmonary Hypertension.
    Chest. 2023 Dec 19:S0012-3692(23)05932-9. doi: 10.1016/j.chest.2023.
    PubMed     Abstract available
    
    
    
64. FAUVEL C, Liu Y, Correa-Jaque P, Kanwar MK, et al
    Do Patients With Low-Risk Pulmonary Arterial Hypertension Really Benefit From Upfront Combination Therapy?: Insight From the AMBITION Trial.
    Chest. 2023;164:1518-1530.
    PubMed     Abstract available
    
    
    October 2023
65. SELF A, Afshar K, Kafi A, Yung G, et al
    An Unexpected Cause of Lung Disease Identified After Lung Transplantation.
    Chest. 2023;164:e111-e115.
    PubMed     Abstract available
    
    
    August 2023
66. MOINZADEH P, Bonella F, Oberste M, Weliwitage J, et al
    Impact of systemic sclerosis-associated interstitial lung disease with and without pulmonary hypertension on survival - a large cohort study of the German network for systemic sclerosis.
    Chest. 2023 Aug 13:S0012-3692(23)05274-1. doi: 10.1016/j.chest.2023.
    PubMed     Abstract available
    
    
    
67. KULARATNE M, Eyries M, Savale L, Humbert M, et al
    Isolated Pulmonary Arteriovenous Malformations Associated With BMPR2 Pathogenic Variants.
    Chest. 2023;164:e23-e26.
    PubMed     Abstract available
    
    
    July 2023
68. CARBONE RG, Monselise A, Puppo F
    Treprostinil and Clinical Outcome in Pulmonary Hypertension and Interstitial Lung Disease: Is All Clear?
    Chest. 2023;164:e21.
    PubMed    
    
    
    
69. DUBROCK HM
    Portopulmonary Hypertension: Management and Liver Transplantation Evaluation.
    Chest. 2023;164:206-214.
    PubMed     Abstract available
    
    
    June 2023
70. SULLIVAN RT, Austin ED
    Developing a Broader Understanding of Pediatric PAH Worldwide.
    Chest. 2023;163:1353-1355.
    PubMed    
    
    
    
71. QIAN Y, Quan R, Chen X, Gu Q, et al
    Characteristics, Long-term Survival, and Risk Assessment of Pediatric Pulmonary Arterial Hypertension in China: Insights From a National Multicenter Prospective Registry.
    Chest. 2023;163:1531-1542.
    PubMed     Abstract available
    
    
    May 2023
72. KOLAITIS NA
    Lung Transplantation for Pulmonary Arterial Hypertension.
    Chest. 2023 May 5:S0012-3692(23)00649-9. doi: 10.1016/j.chest.2023.
    PubMed     Abstract available
    
    
    
73. SCARPATO BM, McDonald J, Bayrak-Toydemir P, Elliott CG, et al
    The Shunt of It.
    Chest. 2023;163:e201-e205.
    PubMed     Abstract available
    
    
    
74. THENAPPAN T, Brittain EL
    Right Ventricular Imaging for Predicting Risk in Pulmonary Arterial Hypertension: The Elephant in the Room.
    Chest. 2023;163:1013-1015.
    PubMed    
    
    
    
75. EL-KERSH K, Zhao C, Elliott G, Farber HW, et al
    Derivation of a Risk Score (REVEAL-ECHO) Based on Echocardiographic Parameters of Patients With Pulmonary Arterial Hypertension.
    Chest. 2023;163:1232-1244.
    PubMed     Abstract available
    
    
    April 2023
76. FORBES LM, Bull TM, Lahm T, Make BJ, et al
    Exercise Testing in the Risk Assessment of Pulmonary Hypertension.
    Chest. 2023 Apr 13:S0012-3692(23)00509-3. doi: 10.1016/j.chest.2023.
    PubMed    
    
    
    March 2023
77. YANG J, Madani MM, Mahmud E, Kim NH, et al
    " Evaluation and Management of Chronic Thromboembolic Pulmonary Hypertension".
    Chest. 2023 Mar 27:S0012-3692(23)00457-9. doi: 10.1016/j.chest.2023.
    PubMed     Abstract available
    
    
    
78. AL-QADI MO, Holbrook J, Ford HJ, Ceppe A, et al
    Prognostic Value of Respiratory Variation in Right Atrial Pressure in Patients with Precapillary Pulmonary Hypertension.
    Chest. 2023 Mar 27:S0012-3692(23)00458-0. doi: 10.1016/j.chest.2023.
    PubMed     Abstract available
    
    
    
79. KITHAS AC, Ramani GV, Cassady SJ
    A Rapidly Evacuated Pericardial Effusion in the Setting of Chronic Pulmonary Hypertension.
    Chest. 2023;163:e137-e139.
    PubMed    
    
    
    February 2023
80. HOWARD LS, Rosenkranz S, Frantz RP, Hemnes AR, et al
    Assessing Daily Life Physical Activity by Actigraphy in Pulmonary Arterial Hypertension: Insights From the Randomized Controlled Study With Selexipag (TRACE).
    Chest. 2023;163:407-418.
    PubMed     Abstract available
    
    
    January 2023
81. BARCO S, Mavromanoli AC, Kreitner KF, Bunck AC, et al
    Pre-existing chronic thromboembolic pulmonary hypertension in acute pulmonary embolism.
    Chest. 2023 Jan 5:S0012-3692(23)00013-2. doi: 10.1016/j.chest.2022.
    PubMed     Abstract available
    
    
    
82. ALOTAIBI M, Shao J, Pauciulo MW, Nichols WC, et al
    Metabolomic Profiles Differentiate Scleroderma-PAH From Idiopathic PAH and Correspond With Worsened Functional Capacity.
    Chest. 2023;163:204-215.
    PubMed     Abstract available
    
    
    December 2022
83. WU S, Hoang HB, Yang JZ, Papamatheakis DG, et al
    Drug-Drug Interactions in the Management of Patients With Pulmonary Arterial Hypertension.
    Chest. 2022;162:1360-1372.
    PubMed     Abstract available
    
    
    
84. LACHANT D, Kennedy E, Derenze B, Light A, et al
    Cardiac Effort to Compare Clinic and Remote 6-Minute Walk Testing in Pulmonary Arterial Hypertension.
    Chest. 2022;162:1340-1348.
    PubMed     Abstract available
    
    
    October 2022
85. MARON BA, Kleiner DE, Arons E, Wertheim BM, et al
    Evidence of Advanced Pulmonary Vascular Remodeling in Obstructive Hypertrophic Cardiomyopathy with Pulmonary Hypertension.
    Chest. 2022 Oct 12. pii: S0012-3692(22)03912-5. doi: 10.1016/j.chest.2022.
    PubMed     Abstract available
    
    
    September 2022
86. NATHAN SD, Deng C, King CS, DuBrock HM, et al
    Inhaled Treprostinil Dose in Pulmonary Hypertension Associated with Interstitial Lung Disease and Its Effects on Clinical Outcomes.
    Chest. 2022 Sep 14. pii: S0012-3692(22)03725-4. doi: 10.1016/j.chest.2022.
    PubMed     Abstract available
    
    
    
87. CHANNICK R, Robert Naeije
    A Right Heart Catheterization for the Diagnosis of Pulmonary Hypertension: Yes, But How?
    Chest. 2022;162:511-513.
    PubMed    
    
    
    
88. SHELBURNE NJ, Frantz RP
    The Oracle of the Auricle?: Optimizing Serial Risk Stratification of Patients With Pulmonary Arterial Hypertension.
    Chest. 2022;162:509-510.
    PubMed    
    
    
    
89. SHAH T, Manthena P, Patel C, Chuah A, et al
    Prognostic Value of Echocardiographic Variables Prior to and Following Initiation of Parenteral Prostacyclin Therapy: An Observational Study.
    Chest. 2022;162:669-683.
    PubMed     Abstract available
    
    
    August 2022
90. YARLAS A, Mathai SC, Nathan SD, DuBrock HM, et al
    Considerations when Selecting Patient-Reported Outcome Measures for Assessment of Health-Related Quality of Life in Patients with Pulmonary Hypertension: A Narrative Review.
    Chest. 2022 Aug 20. pii: S0012-3692(22)03649.
    PubMed     Abstract available
    
    
    
91. MCCARTHY BE, McClelland RL, Appleby DH, Moutchia JS, et al
    BMI and Treatment Response in Patients With Pulmonary Arterial Hypertension: A Meta-analysis.
    Chest. 2022;162:436-447.
    PubMed     Abstract available
    
    
    July 2022
92. MORRIS TA, Fernandes TM, Channick R
    How we do it: evaluation of dyspnea and exercise intolerance after acute pulmonary embolism.
    Chest. 2022 Jul 2. pii: S0012-3692(22)01215-6. doi: 10.1016/j.chest.2022.
    PubMed     Abstract available
    
    
    June 2022
93. SCHWIENING M, Swietlik EM, Pandya D, Burling K, et al
    Different Cytokine Patterns in BMPR2-Mutation-Positive Patients and Patients With Pulmonary Arterial Hypertension Without Mutations and Their Influence on Survival.
    Chest. 2022;161:1651-1656.
    PubMed    
    
    
    May 2022
94. HADDAD F, Contrepois K, Amsallem M, Denault AY, et al
    The Right Heart Network and Risk Stratification in Pulmonary Arterial Hypertension.
    Chest. 2022;161:1347-1359.
    PubMed     Abstract available
    
    
    April 2022
95. MA X, Yu D, Jie B, Li LL, et al
    Endovascular Treatment of Central Pulmonary Arterial Pseudoaneurysms in the Context of Silicosis Combined with Pulmonary Tuberculosis.
    Chest. 2022 Apr 28. pii: S0012-3692(22)00880-7. doi: 10.1016/j.chest.2022.
    PubMed    
    
    
    
96. KHIRFAN G, Melillo CA, Al Abdi S, Lane JE, et al
    Impact of Esophageal Pressure Measurement on Pulmonary Hypertension Diagnosis in Obese Patients.
    Chest. 2022 Apr 8. pii: S0012-3692(22)00592-X. doi: 10.1016/j.chest.2022.
    PubMed     Abstract available
    
    
    
97. CONDON DF, Agarwal S, Chakraborty A, Auer N, et al
    Novel Mechanisms Targeted by Drug Trials in Pulmonary Arterial Hypertension.
    Chest. 2022;161:1060-1072.
    PubMed     Abstract available
    
    
    
98. VANDERPOOL RR, Hunter KS, Insel M, Garcia JGN, et al
    The Right Ventricular-Pulmonary Arterial Coupling and Diastolic Function Response to Therapy in Pulmonary Arterial Hypertension.
    Chest. 2022;161:1048-1059.
    PubMed     Abstract available
    
    
    February 2022
99. GENTY T, Wirth C, Humbert M, Fadel E, et al
    Pulmonary Endarterectomy in Patients With Myeloproliferative Neoplasms.
    Chest. 2022;161:552-556.
    PubMed    
    
    
    September 2021
100. MARRA AM, Sherman AE, Salzano A, Guazzi M, et al
     Right Heart-Pulmonary Circulation Unit Involvement in Left-sided Heart Failure: Diagnostic, Prognostic and Therapeutic Implications. From the Forgotten Chamber to the Chamber of Secrets.
     Chest. 2021 Sep 27. pii: S0012-3692(21)04062-9. doi: 10.1016/j.chest.2021.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Pulmonary Hypertension is free of charge.